9tcc: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "9tcc" [edit=sysop:move=sysop] |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==African Horse Sickness Virus serotype 4 VP2 homotrimer== | |||
<StructureSection load='9tcc' size='340' side='right'caption='[[9tcc]], [[Resolution|resolution]] 3.11Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[9tcc]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/African_horse_sickness_virus_4 African horse sickness virus 4]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9TCC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9TCC FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.11Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9tcc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9tcc OCA], [https://pdbe.org/9tcc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9tcc RCSB], [https://www.ebi.ac.uk/pdbsum/9tcc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9tcc ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/A0A0B5GT51_AHSV A0A0B5GT51_AHSV] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
African horse sickness virus (AHSV) is a lethal equine pathogen with no licensed vaccine other than vaccines containing attenuated virus, which pose safety risks. Endemic to sub-Saharan Africa, AHSV has caused epizootics in Spain and Portugal, Cyprus, Morocco, the Middle East, India and Pakistan and, most recently, Thailand. Here, we resolve the 3.11 A cryo-EM structure of full-length VP2 from AHSV serotype 4, adopting its native triskelion architecture and shedding light on an alpha-helical domain anchoring the triskelion core, which is absent in other structurally characterized orbiviruses. Structure-guided mapping identified a subdomain of VP2 as a key target of neutralizing antibodies. Displayed on nanoparticles using the SpyCatcher/SpyTag technology, the domain conferred complete protection from clinical disease after viral challenge infection in mice and elicited robust and long-lasting immune responses in horses, the target species of AHSV. These findings provide a structural blueprint for the next generation of recombinant vaccines against AHSV and related orbiviruses. | |||
Cryo-EM structure of African horse sickness virus VP2 receptor-binding protein enables nanoparticle vaccine design.,Martinez-Castillo A, Aebischer A, Toneatti P, Fu L, Vitour D, Sailleau C, Hoffmann B, Franzke K, Eschbaumer M, Weber S, Calvo Pinilla E, Ortego J, Gil-Carton D, Breard E, Zientara S, Kortekaas J, Beer M, Abrescia NG Nat Commun. 2026 Jul 4. doi: 10.1038/s41467-026-75067-9. PMID:42401561<ref>PMID:42401561</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 9tcc" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: African horse sickness virus 4]] | |||
[[Category: Large Structures]] | |||
[[Category: Abrescia NGA]] | |||
[[Category: Aebischer A]] | |||
[[Category: Beer M]] | |||
[[Category: Breard E]] | |||
[[Category: Fu L]] | |||
[[Category: Kortekaas J]] | |||
[[Category: Martinez-Castillo A]] | |||
[[Category: Zientara S]] | |||
